



**FOR PERSONAL USE ONLY NOT TO BE REPRODUCED WITHOUT PERMISSION OF THE EDITOR**

## **DIRECT ORAL ANTICOAGULANTS: A GUIDE TO APPROPRIATE PRESCRIBING IN ADULTS**

- Direct oral anticoagulants (DOACs) have different dose criteria depending on the specific indication
- Dosing errors with DOACs can result in patient harm; under-dosing may increase the risk of embolic events, while over-dosing can result in an increased risk of bleeding
- The patient's age, weight, renal function and concomitant medication should be considered when selecting the dose of a DOAC for a specific indication
- Clinically significant drug-drug interactions can occur with DOACs

### **INTRODUCTION**

Direct oral anticoagulants (DOACs), also known as non-vitamin K oral anticoagulants (NOACs), are alternatives to vitamin K anticoagulants (VKAs) such as warfarin. DOACs selectively target thrombin (dabigatran etexilate) or factor Xa (apixaban, edoxaban and rivaroxaban).<sup>1</sup> DOACs have a number of indications and were first authorised in Europe in 2008 for thromboprophylaxis post orthopaedic surgery and for stroke prevention in non-valvular atrial fibrillation (NVAf) in 2011.<sup>2</sup> The use of DOACs has increased globally;<sup>1,3</sup> an Irish study found a rapid increase in the prescribing of DOACs from 2013 to 2017.<sup>4</sup>

While DOACs have a number of advantages over warfarin such as a rapid onset of action, predictable dose-response with fixed doses, less drug and food interactions and a lack of requirement for routine coagulation monitoring,<sup>1,5-7</sup> there are challenges in the prescribing of DOACs and the absolute benefits of DOACs over VKAs are modest.<sup>1</sup> **Dosing errors with DOACs have been reported in clinical practice, resulting in patient harm.**<sup>8-11</sup> The dose of DOAC depends on the **specific indication** and on patient factors including age, weight, renal function and concomitant medication. **It is important to be aware that dose reduction criteria applicable to the management of NVAf may not apply to acute venous thromboembolism (VTE).** The appropriate use of DOACs requires a considered approach to many practical aspects,<sup>5</sup> which will be discussed in this bulletin.

### **PHARMACOLOGY**

The pharmacological properties of the DOACs are summarised in table 1. Apixaban, edoxaban and rivaroxaban are direct factor Xa inhibitors,<sup>12-14</sup> while dabigatran etexilate is a prodrug that is rapidly converted by a serum esterase to dabigatran, which is a direct thrombin inhibitor.<sup>15</sup> All DOACs are substrates of P-glycoprotein (P-gp) and the factor Xa inhibitors (edoxaban to a lesser extent than apixaban and rivaroxaban) are metabolised by cytochrome P450 isoenzymes (CYP).<sup>12-18</sup> **All DOACs are at least partially renally cleared,** therefore there is a potential for drug accumulation in patients with renal impairment.<sup>12-18</sup> **DOACs have a relatively short half-life (approximately 12 hours)** in patients with normal renal function; the half-life may increase in patients with renal impairment.<sup>1</sup>

**Table 1: Pharmacological properties of direct oral anticoagulants<sup>1,5,19</sup>**

Characteristic	Apixaban	Dabigatran etexilate	Edoxaban	Rivaroxaban
Target	Factor Xa	Thrombin	Factor Xa	Factor Xa
Bioavailability	50%	6 to 7%	62%	66%*
Time to peak levels	3 to 4 hours	0.5 to 2 hours	1 to 2 hours	2 to 4 hours
Half-life	Approx. 12 hours	12 to 14 hours	10 to 14 hours	9 to 13 hours
Renal clearance %	27%	>80%	50%	33%
Substrate for P-gp	Yes	Yes	Yes	Yes
Metabolism via cytochrome P450 enzymes %	<32%	No	<5%	57%

*P-gp – P-glycoprotein; \*applies to the 15mg and 20mg doses given once a day without food; bioavailability 80-100% when these doses are given with food*

### **INDICATIONS**

DOACs are authorised and reimbursed in Ireland for 1) stroke prevention in patients with NVAf and other risk factors, 2) treatment and prevention of recurrence of deep vein thrombosis (DVT) or pulmonary embolus (PE) in adults and 3) thromboprophylaxis post-elective total hip replacement (THR) and total knee replacement (TKR) surgery (excluding edoxaban).<sup>2</sup> **Warfarin remains the OAC of choice for many indications including: mechanical heart valves, valvular AF, antiphospholipid syndrome and in those with severe renal impairment.**<sup>2</sup> Adverse effects associated with DOACs include bleeding (e.g. gastrointestinal (GI), epistaxis, genitourinary, heavy menstrual bleeding), anaemia, dizziness, abnormal liver function tests and abdominal pain.<sup>12-18</sup>

**Stroke prevention:** Randomised controlled trials (RCTs) have shown that DOACs are as effective as warfarin in preventing stroke in patients with NVAf<sup>20-23</sup>; evidence suggests DOACs are associated with a reduced risk of intracerebral haemorrhage.<sup>20-28</sup> DOACs are recommended by many specialists for stroke prevention in patients with NVAf.<sup>1,5,28,29</sup> The HSE Medicines Management Programme (MMP) recommends warfarin as a first-line OAC when the time in the therapeutic range (TTR) is >70%, or apixaban if a DOAC is preferred.<sup>2</sup> **DOACs are contraindicated in patients with mechanical heart valves due to an increased risk of thromboembolic and bleeding events.**<sup>1,8,29</sup>

**Prevention of VTE after major orthopaedic surgery:** RCTs have found DOACs to be as effective (apixaban and dabigatran) or more effective (rivaroxaban) than heparin for preventing VTE following elective THR/TKR surgery.<sup>30-40</sup> Guidelines recommend DOACs as an option for VTE prophylaxis if the risk of VTE outweighs the risk of bleeding in patients having a THR/TKR.<sup>8,41,42</sup>

**Treatment and prevention of recurrent VTE:** The management of VTE requires anticoagulation therapy.<sup>43,44</sup> RCTs found DOACs to be non-inferior to VKAs in the management of patients with VTE, with similar or reduced rates of major bleeding.<sup>1,43-50</sup> **Apixaban and rivaroxaban do not require initial parenteral treatment with heparin**, however dabigatran and edoxaban do.<sup>12,13,16-18,20</sup> Guidelines recommend DOACs in preference to VKAs for the treatment of VTE in suitable patients.<sup>1,43,51</sup> The duration of anticoagulation needs to be individualised to the patient, whereby **the risk of recurrent VTE needs to be weighed up against the risk of bleeding.**<sup>44</sup> Treatment with OAC is recommended for at least 3 months;<sup>43,51</sup> extended use is considered for those at risk of recurrent VTE (e.g. those with an unprovoked VTE, recurrent VTE or a persistent risk factor).<sup>43,44,51-53</sup> Depending on the DOAC used, a dose reduction for long term secondary prevention may be indicated following six months of initial therapy.<sup>44,54</sup> Evidence suggests that DOACs are effective for the treatment of VTE in patients with cancer (an unauthorised indication),<sup>55-58</sup> however there is an increased risk of bleeding especially in patients with cancer of the GI tract.<sup>1,55,56</sup> A DOAC may be considered on specialist advice in individual patients with cancer, such as those with a specific cancer (e.g. excluding GI or urothelial cancer), who are without risk factors for bleeding or potential drug-drug interactions (including chemotherapy) and a stable platelet count of  $>50 \times 10^9/L$ .<sup>43,44,51,59</sup>

**Other indications:** Rivaroxaban (2.5 mg) is also authorised (not currently reimbursed) for use in combination with aspirin for the prevention of atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events.<sup>14,60</sup> It is also authorised (not reimbursed) for use with aspirin alone or with dual antiplatelet therapy for the prevention of atherothrombotic events after an acute coronary syndrome with elevated cardiac biomarkers.<sup>14,61</sup> Emerging evidence suggests that DOACs may be effective in patients with bioprosthetic valves.<sup>62,63</sup>

**Contraindications:** All DOACs are contraindicated in patients with hypersensitivity reactions to DOACs, active bleeding or anatomical lesions predisposing to life-threatening bleeding, advanced liver disease with coagulopathy or bleeding and concomitant administration with other anticoagulants (except under specific circumstances); individual DOACs are also contraindicated or not recommended in conditions including advanced renal disease, prosthetic valves and antiphospholipid syndrome, and in pregnancy and breastfeeding.<sup>15-18</sup> Due to a lack of data, the use of DOACs is not recommended in patients who have had gastric bypass surgery or gastrectomy due to concerns about reduced absorption;<sup>64-66</sup> further studies are needed.

### **ASPECTS TO CONSIDER WHEN PRESCRIBING A DOAC**

The decision to commence a patient on a DOAC should be based on the benefits (prevention of an embolus) versus the risks (e.g. bleeding) for the individual patient.<sup>6</sup> Baseline investigations include a full blood count, renal and hepatic function, which should be assessed prior to commencing a DOAC. A number of factors need to be considered when starting a patient on a DOAC for a specific indication including the dose and duration of the DOAC, renal function, age, weight, risk of bleeding, drug interactions, cost and patient education.

### **DOAC dosing**

Each DOAC has different dose recommendations depending on the specific indication and has different dose reduction criteria for individual patients;<sup>5-7</sup> **the Summary of Product Characteristics (SmPC) (available on [www.hpra.ie](http://www.hpra.ie) and [www.medicines.ie](http://www.medicines.ie)) which contains all prescribing information should be consulted when prescribing for an individual patient.** The following factors need to be considered when choosing the appropriate dose of a DOAC: **the indication for the DOAC, patient's age, weight, renal function, concomitant medications and risk of bleeding.**<sup>12-18,67</sup> **It is important to be aware that dose reduction advice for individual agents may pertain to NVAf and not to acute VTE.** Under-dosing may increase the risk of embolic events while over-dosing can result in an increased risk of bleeding.<sup>6</sup> **Risk factors for dosing errors include older age, renal impairment, concomitant medications and use in patients with a higher risk of bleeding.**<sup>9,10</sup> Of note, apixaban and rivaroxaban were among the most commonly reported antithrombotics to be involved in medication incidents (including dosing errors) in Irish hospitals between 2017-2018.<sup>68</sup>

### **Administration**

Dabigatran comes as a capsule formulation **and should remain in the original container.**<sup>15,16</sup> **The capsule must not be opened or crushed as this may result in an increased bioavailability (up to 75%) and a subsequent increased risk of bleeding.**<sup>5,15,16</sup> The dabigatran capsule must be swallowed whole with a glass of water.<sup>15,16</sup> Apixaban, rivaroxaban and edoxaban may be crushed and mixed with fluid and/or administered via nasogastric tubes if required.<sup>5,12-18</sup> **Rivaroxaban 15mg and 20mg must be taken with food;**<sup>18</sup> thromboembolic events have been reported when rivaroxaban is taken on an empty stomach.<sup>8</sup>

### **Renal impairment**

All DOACs are excreted by the kidneys and dose adjustments may be required for some indications in those with renal impairment,<sup>5,6</sup> therefore **renal function must be measured prior to selecting the dose of any DOAC. Renal function should be assessed by calculating the estimated creatinine clearance (CrCl) using the Cockcroft-Gault method** (see figure 1).<sup>5,6</sup> The current consensus is that renal function should be assessed at least annually for

those on long-term DOACs, with more frequent monitoring for those in clinical situations where renal function may decline and in patients with impaired renal function at baseline.<sup>5,6</sup> The European Heart Rhythm Association recommends that if the CrCl is  $\leq 60$  mL/min, the frequency of monitoring (in months) can be guided by the CrCl divided by 10.<sup>5</sup> For example, if the CrCl is 30 mL/min, the renal function and dose should be reassessed every 3 months.<sup>6</sup> **The risk of developing renal impairment increases with age, therefore the monitoring of renal function over time is important in those on DOACs long-term** (e.g. patients with NVAF or on extended preventive therapy for VTE).<sup>6</sup> Note that the recommendations for dose reduction in renal impairment for individual DOACs may differ depending on the specific indication (e.g. in severe renal impairment, the dose of apixaban should be reduced in patients with NVAF, but NOT for patients with VTE); refer to the specific SmPC for the individual DOAC.<sup>12</sup>

### **Figure 1: Cockcroft and Gault formula for calculation of estimated creatinine clearance<sup>5,69</sup>**

$$\text{Estimated creatinine clearance in mL/minute} = \frac{(140 - \text{Age}) \times \text{Weight}^* \times \text{Constant}}{\text{Serum creatinine}}$$

Age in years; weight in kilograms; serum creatinine in micromole/litre; constant = 1.23 for men, 1.04 for women

\*actual body weight was used in the DOAC clinical trials

In general, **use of dabigatran is contraindicated in patients with CrCl  $< 30$  mL/min, and use of apixaban, edoxaban and rivaroxaban is not recommended in those with CrCl  $< 15$  mL/min.**<sup>5,12-18</sup> An observational study of patients on DOACs with NVAF in routine clinical practice found that 43% of patients did not have appropriate dose reduction according to renal function (associated with higher risk of major bleeding) and 13% had inappropriate dose reduction with normal renal function (associated with higher risk of stroke).<sup>70</sup> A possible decreased efficacy of edoxaban 60mg daily compared with warfarin was observed in patients with AF with a CrCl  $> 95$  mL/min,<sup>5,13</sup> edoxaban for NVAF should only be used in those with a high CrCl after careful evaluation of the individual thromboembolic and bleeding risk.<sup>5,8,13</sup>

### **Weight**

In general, there is limited data available on the use of DOACs in patients at extremes of body weight (BW) (e.g.  $< 50$  kg and  $> 120$  kg), as these patients were underrepresented in clinical trials.<sup>1,5</sup> **Low BW ( $< 50$  kg) may increase exposure to a DOAC, with an increased risk of bleeding and higher mortality.**<sup>5,71-73</sup> Low BW may also be associated with other risk factors such as increased age, frailty, cancer and renal impairment, therefore caution is needed when these patients are being anticoagulated.<sup>5</sup> Some resources recommend that DOACs should be avoided or used with caution in those  $< 50$  kg;<sup>15,16,72-75</sup> there are dose reduction criteria for underweight patients ( $< 60$  kg) prescribed apixaban and edoxaban.<sup>12,13</sup>

**There are concerns that DOAC underdosing could occur in patients with morbid obesity** (BW  $> 120$  kg or a body mass index [BMI] of  $> 40$  kg/m<sup>2</sup>).<sup>1,5,76,77</sup> Guidelines recommend that standard doses of DOACs are used in patients with a BW of  $\leq 120$  kg or a BMI  $\leq 40$  kg/m<sup>2</sup>, and suggest that alternative OACs should be considered for patients with a BW  $> 120$  kg or BMI of  $> 40$  kg/m<sup>2</sup>.<sup>76,78</sup>

### **Risk of bleeding**

**It is important to consider that all OACs including DOACs are associated with an increased risk of bleeding.** There is evidence to suggest that DOACs (excluding apixaban) have a higher risk of GI bleeding compared to warfarin.<sup>21-22,79-83</sup> Factors associated with an increased risk of bleeding include older age, low body weight  $\leq 60$  kg, impaired renal function, concomitant medications (e.g. antiplatelets, non-steroidal anti-inflammatory drugs [NSAIDs], selective serotonin re-uptake inhibitors [SSRIs] and systemic steroids), history of GI bleeding, recent surgery, frailty or falls risk, anaemia and thrombocytopenia.<sup>5</sup> In some patients proton pump inhibitors may be considered to reduce the risk of GI bleeding, especially in those with a history of GI bleeding or ulcer and in patients requiring concomitant use of dual antiplatelet therapy.<sup>5</sup> **Use of a score such as HAS-BLED may be useful for an estimation of bleeding risk and to address any modifiable risk factors for bleeding.**<sup>6</sup>

### **Drug interactions**

**DOACs are associated with less drug interactions than VKAs, however clinically significant drug interactions can occur.** The SmPC of the individual DOAC should be reviewed for patients who are prescribed potentially interacting medicines.

**Pharmacokinetic interactions:** As all DOACs are substrates for the efflux transporter P-gp,<sup>1,2,5,52</sup> drugs that induce or inhibit P-gp may affect DOAC plasma concentration, resulting in an increased risk of thrombosis or bleeding respectively.<sup>2,54</sup> **Factor Xa inhibitors, in particular apixaban and rivaroxaban are substrates for CYP3A4,** therefore drug interactions may occur when these drugs are co-administered with CYP3A4 inducers or inhibitors.<sup>1,2,5,54</sup> To reduce the risk of bleeding with concurrent CYP3A4/P-gp inhibitors, DOACs may require dose adjustment (e.g. dabigatran, edoxaban) or the interacting drugs should be avoided altogether.<sup>84</sup> Other factors such as the indication for the DOAC, the patient's age, weight and renal function which can also impact on a clinically relevant drug interaction occurring must be considered.<sup>5</sup>

**Pharmacodynamic (PD) interactions:** Patients on DOACs are at risk of potential PD drug interactions when prescribed other medications that can also increase the risk of bleeding (e.g. NSAIDs, systemic steroids, antiplatelets and SSRIs).<sup>2,5,12-18,85</sup> DOACs are contraindicated with other anticoagulants (except in specific circumstances e.g. switching from DOAC to VKA).<sup>14-18</sup>

## Patient education

Patient education on use of a DOAC is important to reduce the risk of medication errors. **The patient should be educated on the importance of strict adherence to the dosing regimen**, how to manage missed doses and how to recognise the signs and minimise the risk of bleeding (e.g. the avoidance of potentially interacting drugs including over-the-counter medicines and excessive alcohol).<sup>5,8,86</sup> Evidence suggests adherence to DOACs ranges from 38 to 99% (depends on the healthcare setting and definition of adherence).<sup>5</sup> **A recent study of patients with NVAF found that discontinuation of OACs (including DOACs) led to a 2 to 3-fold higher risk of ischaemic stroke than those who continued OACs.**<sup>87</sup> Use of DOACs may be challenging in patients who are unable to take their medication as prescribed.<sup>88</sup> Methods to improve adherence include education (e.g. leaflets, instructions at initiation of DOAC therapy and at every prescription renewal, patient anticoagulation cards), medication boxes (not suitable for dabigatran), smartphone applications and once daily regimens where authorised.<sup>5</sup> **Patients should be informed of the importance of not missing doses, as missing one or two doses of a DOAC may leave the patient inadequately anticoagulated.**<sup>88</sup> The forgotten dose may be taken up until 50% of the dosing interval has lapsed (i.e. 12 hours in once daily dosing and 6 hours in twice daily dosing); after this time, the forgotten dose should be skipped, and the next dose taken.<sup>12-18,29</sup> This advice may vary for specific indications (e.g. prevention of VTE following orthopaedic surgery).<sup>15</sup>

## MONITORING OF A PATIENT PRESCRIBED A DOAC

**Patients on DOACs require ongoing monitoring**; the lack of routine INR monitoring and less frequent interactions with healthcare professionals may result in an increased risk of adverse outcomes.<sup>2,4,88</sup> Patients commenced on a DOAC should be reviewed after 1 month initially, followed by at least every 6 to 12 months (the follow-up interval depends on factors including age, frailty, renal function, comorbidities).<sup>5</sup> **At each review it is important to ensure that the patient is on the correct dose of DOAC and for the appropriate duration in terms of the indication, and to check/assess the patient's current age, weight, renal function and concomitant medication.**<sup>2,5,8</sup> The patient should be reviewed for adverse effects, and risks (or events) of thromboembolism and bleeding; modifiable risk factors for bleeding should be identified. The patient should be **reminded of the importance of strict adherence to the dosing regimen** and how to minimise the risk of bleeding. Investigations such as haemoglobin, renal and hepatic function should be undertaken at least annually (more frequently if clinically indicated).<sup>2</sup>

## OTHER CONSIDERATIONS

**Reversal of DOACs:** DOACs have short half-lives and, in the case of bleeding, treatment is largely supportive. A specific reversal agent idarucizumab is available for dabigatran in the event of life-threatening bleeding.<sup>1,5</sup> For patients who present with bleeding, identify when the last DOAC was taken, and assess if there is a possibility of double DOAC intake, incorrect dosing, worsening renal function, or if the patient is on any medication that may contribute to bleeding (e.g. NSAIDs, SSRIs).<sup>5,29</sup> For mild bleeding the next DOAC dose should be delayed or discontinued, and patient education should be reinforced.<sup>5,29</sup>

**Surgical procedures:** Peri-procedural decisions on when to stop a DOAC are usually made by specialists in a hospital setting and depend on the type of surgery and the associated bleeding risk.<sup>5,29</sup> The indication for the DOAC and patient characteristics (e.g. age, renal function, concomitant medication and history of bleeding complications) also need to be considered.<sup>5</sup> In the event of temporary discontinuation peri-operatively, bridging with LMWH is not required for DOACs.<sup>5</sup> In general, for procedures with minimal risk of bleeding (e.g. routine dental work), DOACs can be continued or a single dose withheld on the morning of the procedure.<sup>1</sup>

**Switching:** It may be necessary to switch patients from warfarin to a DOAC and from DOACs to warfarin. Guidance on switching is specific to each DOAC and may vary by indication; information is available in the SmPC.

## SUMMARY OF THE PRACTICAL ASPECTS OF PRESCRIBING DOACs<sup>5,29</sup>

Before prescribing a DOAC consider the following:
<ul style="list-style-type: none"><li>• Establish the indication for anticoagulation and the intended duration</li><li>• Check baseline bloods including haemoglobin, renal and liver function</li><li>• Choose the optimal anticoagulant and the correct dose for the specific patient (check the Summary of Product Characteristics)</li><li>• Consider possible drug interactions</li><li>• Consider the need for a proton pump inhibitor</li><li>• Provide patient education emphasising the need for adherence to avoid a pro-thrombotic state and how to recognise the signs and minimise the risk of bleeding</li><li>• Organise follow-up</li></ul>
↓
Follow-up (initially after 1 month) consider the following
<ul style="list-style-type: none"><li>• Assess the optimal DOAC and dose for your specific patient</li><li>• Check for thromboembolic and bleeding events</li><li>• Assess adherence and reinforce education</li><li>• Check for side effects</li><li>• Review medications including over-the-counter medicines; assess for drug interactions</li><li>• Decide if bloods (haemoglobin, renal and liver function) required: (at least yearly; 6 monthly if ≥75 years; more frequently if creatinine clearance ≤60mL/min; as required if intercurrent condition)</li><li>• Assess modifiable risk factors for bleeding (e.g. uncontrolled hypertension, medication predisposing to bleeding, excessive alcohol intake)</li></ul>

List of references available on ePublication on [www.nmic.ie](http://www.nmic.ie). Date of publication: February 2021

Every effort has been made to ensure that this information is correct and is prepared from the best available resources at our disposal at the time of issue. Prescribers are recommended to refer to the individual Summary of Product Characteristics for specific information on a drug.

## **Direct oral anticoagulants (DOACs): a guide to appropriate prescribing in adults**

### **References (26<sup>th</sup> February 2021)**

1. Chan N, Sobieraj-Teague M, Eikelboom JW, Direct oral anticoagulants: evidence and unresolved issues, *Lancet* November 2020;396:1767-76
2. Medicines Management Programme, Oral anticoagulants for stroke prevention in non-valvular atrial fibrillation, Version 1.2 published March 2019 available on <https://www.hse.ie/eng/about/who/cspd/ncps/medicines-management/preferred-drugs/oral-anticoagulants-for-stroke-prevention-in-non-valvular-atrial-fibrillation.pdf> (accessed 13th January 2021)
3. Rose A, Goldberg R, McManus D et al, Anticoagulant Prescribing for Non-Valvular Atrial Fibrillation in the Veterans Health Administration, *Journal of the American Health Association* 2019;8(17) available on <https://www.ahajournals.org/doi/epub/10.1161/JAHA.119.012646> on the 11th January 2021
4. Kennedy C, Ni Choitir C, Clarke S et al, Direct oral anticoagulants uptake and an oral anticoagulation paradox, *British Journal Clinical Pharmacology* 2020;86:392-397
5. European Society of Cardiology: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, *European Heart Journal* 2018;39:1330-1393
6. Specialist Pharmacy Service: Direct acting oral anticoagulants (DOACs) in renal impairment: practice guide to dosing issues (v3-Feb 2020) accessed from [www.sps.nhs.uk](http://www.sps.nhs.uk) on the 18<sup>th</sup> December 2020
7. Erskine D (Editorial), DOAC dosing in renal impairment, *Drug and Therapeutics Bulletin* 2019;DOI: 10.1136/dtb.2019.000013
8. NICE – Anticoagulants, including direct-acting oral anticoagulants (DOACs) accessed from [www.nice.org.uk](http://www.nice.org.uk) on the 11<sup>th</sup> December 2020
9. Ferrat E, Fabre J, Galletout P et al, Inappropriate prescriptions of direct oral anticoagulants among patients with atrial fibrillation in general practice: a cross-sectional analysis of the French CACAO cohort study, *British Journal General Practice* 2020; doi.org/10.3399/bjgp20X714005
10. Zhang ZX, van de Garde EMW, Sohne M, et al, Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions, *British Journal Clinical Pharmacology* 2020;86:1567-1574
11. Steinberg B, Shrader P, Thomas L et al, Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes, *Journal of the American College of Cardiology* 2016;68(24):2597-2604
12. SmPC Eliquis® (apixaban) accessed [www.medicines.ie](http://www.medicines.ie) on the 27<sup>th</sup> November 2020
13. SmPC Lixiana® (edoxaban) accessed [www.medicines.ie](http://www.medicines.ie) on the 12<sup>th</sup> February 2021
14. SmPC 2.5mg Xarelto® (rivaroxaban) accessed [www.medicines.ie](http://www.medicines.ie) on the 27<sup>th</sup> November 2020
15. SmPC 75mg Pradaxa® (dabigatran etexilate) accessed [www.medicines.ie](http://www.medicines.ie) on the 27<sup>th</sup> November 2020
16. SmPC 150mg Pradaxa® (dabigatran etexilate) accessed [www.medicines.ie](http://www.medicines.ie) on the 27<sup>th</sup> November 2020

17. SmPC 10mg Xarelto® (rivaroxaban) accessed [www.medicines.ie](http://www.medicines.ie) on the 27<sup>th</sup> November 2020
18. SmPC 20mg Xarelto® (rivaroxaban) accessed [www.medicines.ie](http://www.medicines.ie) on the 27<sup>th</sup> November 2020
19. Heidbuchel H, Verhamme P, Alings M et al, Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation (published 2015), *Europace* (2015) 17, 1467–1507 doi:10.1093/europace/euv309 (accessed 16<sup>th</sup> February 2021)
20. Granger CB et al, Apixaban versus Warfarin in Patients with Atrial Fibrillation, *N Engl J Med* 2011;365:981-92
21. Connolly SJ et al, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, *N Engl J Med* 2009;361:1139-51
22. Giugliano RP, Ruff CT, Braunwald E et al, Edoxaban versus warfarin in patients with atrial fibrillation, *N Engl J Med* 2013;369:2093-2104
23. Patel MR et al, Rivaroxaban versus Warfarin in Non-valvular Atrial Fibrillation, *N Engl J Med* 2011;365:883-91
24. Lopez-Lopez JA, Sterne JA, Thom H, et al, Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis, *BMJ* 2017;359:j5058
25. Ruff CT, Giugliano RP, Braunwald E et al, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, *Lancet* 2014;383(9921):955-962
26. Diener HC, Hankey GJ, Easton JD et al, Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation, *European Heart Journal Supplements* (2020) 22 (Supplement I), I13–I21
27. Bouget J, Balusson F, Maignan M et al, Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study, *British Journal Clinical Pharmacology* 2020;86:2519-2529
28. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical practice Guidelines and the Heart Rhythm Society; 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guidelines for the Management of Patients with Atrial Fibrillation, *Circulation* 2019;140:e125-e151
29. Quality and Safety in Practice Committee (ICGP): Quick Reference Guide Practical use of Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation in General Practice February 2020
30. Turpie A, Lassen M, Eriksson B et al, Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies, *Thromb Haemostat* 2011 Mar;105(3):444-53
31. Lassen MR, Raskob G, Gallus A, et al, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial, *Lancet* 2010;375:807-15
32. Lassen MR et al, Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement, *NEJM* 2010;363:2487-98
33. Eriksson B et al, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, *J Thromb Haemost* 2007;5:2178-85

34. Lassen M et al, Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty, *NEJM* 2008;358:2776-86
35. Turpie A et al, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, *Lancet* 2009;373:1673-80
36. Eriksson B et al, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, *Lancet* 2007;370:949-56
37. Eriksson B et al, Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty, *NEJM* 2008;358:2765-75
38. Eriksson B et al, Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II\*). A randomised, double-blind, non-inferiority trial, *Thrombosis Haemostasis* 2011;105:721-9
39. Fuji T, Wang CJ, Fujita S et al, Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial, *Thromb Res.* 2014;134:1198-1204
40. Fuji T, Fujita S, Kawai Y et al, Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V, *Thromb J* 2015;13:27: DOI 10.1186/s12959-015-0057-x
41. NICE Venous thromboembolism in over 16s: reducing the risk of hospital acquired deep vein thrombosis or pulmonary embolism, March 2018 accessed from [www.nice.org.uk](http://www.nice.org.uk) on the 18<sup>th</sup> December 2020
42. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2):e278S-e325S.
43. Konstantinides SV, Meyer G, Becattini C et al, The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS), *Eur Respir J* 2019;54:1901647. Doi:10.1183/13993003.01647-2019
44. Duffett L, Castellucci L, Forgie M, Pulmonary embolism: update on management and controversies, *BMJ* 2020;370:m2177
45. Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. *Cochrane Database of Systematic Reviews* 2015, Issue 12. Art. No.: CD010957. DOI: 10.1002/14651858.CD010957.pub2
46. The EINSTEIN investigators, Oral rivaroxaban for symptomatic venous thromboembolism, *NEJM* 2010;363:2499-510
47. The EINSTEIN-PE Investigators, Oral rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism, *NEJM* 2012;366:1287-97
48. Schulman S, Kearon C, Kakkar AK, et al, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, *NEJM* 2009;361:1-11
49. Agnelli G, Buller HR, Cohen A et al, AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism, *NEJM* 2013;369:799-808

50. Buller HR, Decousus H, Grosso MM et al, Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism, *N Engl J Med* 2013;369:1406-15
51. NICE Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, March 2020 accessed from [www.nice.or.uk](http://www.nice.or.uk) on the 30<sup>th</sup> December 2020
52. Agnelli G, Buller HR, Cohen A et al, AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism, *NEJM* 2013;368:699-708
53. Weitz JI, Lensing AWA, Prins MH et al, EINSTEIN CHOICE Investigators, Rivaroxaban or aspirin for extended treatment of venous thromboembolism, *NEJM* 2017;376:1211-22
54. Coulis A, Mackey W, A review of the efficacy and safety profiles of the novel oral anticoagulants in the treatment and prevention of venous thromboembolism, *clinical Therapeutics* 2018;40(12):2140-2167
55. Raskob GE, van Es N, Verhamme P et al, Hokusai VTE Cancer Investigators, Edoxaban for the Treatment of Cancer Associated Venous Thromboembolism, *N Engl J Med* 2018;378:615-24
56. Young AM, Marshall A, Thirlwall J et al, Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D), *J Clin Oncol* 2018;36:2017-23
57. McBane RD2nd, Wysokinski WE, Le-Rademacher JG et al, Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial, *J Thromb Haemost* 2020;18:411-21
58. Agnelli G, Becattini C, Meyer G et al, Apixaban for the treatment of venous thromboembolism associated with cancer, *NEJM* 2020;382 (17):1599-607
59. Carrier M, Blais N, Crowther M et al, Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus, *Curr Oncol* 2018;25(5):329-337
60. NICE Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease, October 2019, accessed at [www.nice.org.uk/](http://www.nice.org.uk/) on the 11<sup>th</sup> December 2020
61. NICE, Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome, March 2015, accessed [www.nice.org.uk/](http://www.nice.org.uk/) on the 11<sup>th</sup> December 2020
62. Guimaraes HP, Lopes RD, de Barros e Silva PGM et al, Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve, *NEJM* 2020;383(22): 2117-26
63. Kheiri B, Przybylowicz R, Simpson T et al, Meta-analysis of direct oral anticoagulants in patients with atrial fibrillation and bioprosthetic valves, *American Journal of Cardiology* 2020 (Article in press) accessed online the 4<sup>th</sup> December 2020
64. Leven C, Hoffmann C, Roche C et al, Impact of bariatric surgery on oral anticoagulants pharmacology, and consequences for clinical practice: a narrative review, *Fundamental & Clinical Pharmacology* 2021;35:53-61
65. Martin K, Lee C, Farrell T et al, Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance, *Am J med* 2017;130:517-524

66. Hakeam H, Al-Sanea N, Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs), *Journal of Thrombosis and Thrombolysis* 2017;43:343-351
67. HSE Medicines Management Programme: anticoagulation prescribing tips Version 2.0 October 2020 available on <https://www.hse.ie/yourmedicines>
68. State Claims Agency, Medication Incidents Report – a review of medication incidents reported by Irish acute hospitals (2017-2018), published August 2020, accessed 17<sup>th</sup> December 2020 on <https://stateclaims.ie/resources>
69. BNF Cockcroft and Gault formula from Prescribing in renal impairment accessed from [www.medicinescomplete.com](http://www.medicinescomplete.com) accessed on the 16<sup>th</sup> December 2020
70. Yao X, Shah N, Sangaralingham L et al, Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction, *American College of Cardiology* 2017;69(23):2779-2790
71. Murakawa Y, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Hayashi Y, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation. *Heart Vessels*. 2020 Aug;35(8):1125-1134
72. Covert K, Branam DL. Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations, *Am J Health Syst Pharm*. 2020 May 19;77(11):865-876
73. De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. *Clin Res Cardiol*. 2017 Aug;106(8):565-572 Park CS, Choi E, Kim H, et al, Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants, *Heart Rhythm*. 2017;14:501-507
74. Chen A, Stecker E, Warden B, Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges, *Journal of The American Heart Association*, 2020;9:e017559
75. British National Formulary – Dabigatran etexilate accessed from [MedicinesComplete](http://www.medicinescomplete.com) on the 25<sup>th</sup> February 2021
76. Martin K, Beyer-Westendorf J, Davidson BL et al, Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH, *J Thrombosis and Haemostasis* 2016;14(6):1308-1313
77. Sebaaly J, Kelley D, Direct Oral anticoagulants in Obesity: A Updated Literature Review, *Annals of Pharmacotherapy* 2020;54(11):1144-1158
78. Zukkoor S, Expert analysis: Antiarrhythmic and DOAC dosing in obesity, *American Journal of Cardiology* July 2019 available on <https://www.acc.org/latest-in-cardiology/articles/2019/07/03/08/22/antiarrhythmic-and-doac-dosing-in-obesity> (accessed on the 17<sup>th</sup> February 2021)
79. Abraham N, Noseworthy P, Yao X et al, Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study, *Gastroenterology* 2017;152(5):1014-1022
80. Miller C, Dorreen A, Martel M et al, Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis, *Clin Gastroenterol Hepatol* 2017;15(11):1674-1683

81. Radadiya D, Devani K, Brahmhatt B et al, Major gastrointestinal bleeding risk with direct oral anticoagulants (DOAC): does the type and dose matter? Results from network meta-analysis of randomised controlled trials, *Gastroenterology* 2020;158:6 Suppl S24-S25
82. Cheung KS, Leung W, Gastrointestinal bleeding in patients on novel oral anticoagulants: risk prevention and management, *World J Gastroenterology* 2017;23(11):1954-1963
83. Radaelli F, Fuccio L, Paggi S et al, What gastroenterologists should know about direct oral anticoagulants, *Digestive and Liver Disease*, 2020;52:1115-1125
84. Kennedy C, Brewer L, Williams D, Drug Interactions. *Medicine* 2020;48(7):450-455
85. Zhang Y, Souverein P, Gardarsdottir H et al, Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: a population-based nested case-control study, *British Journal Clinical Pharmacology* 2020;86:1150-1164
86. Capiou A, Mehuys E, Van Tongelen I et al, Community pharmacy-based study of adherence to non-vitamin K antagonist oral anticoagulants, *Heart* 2020;0:1-7 doi:10.1136/heartjnl-2020-316781
87. Garcia Rodriguez LA, Cea Soriano L, Munk Hald S et al, Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke, *Heart* 2020;0:1-7. Doi:10.1136/heartjnl-2020-317887
88. Leung L, Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects accessed on Uptodate on [https://www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects?search=direct%20oral%20anticoagulants&source=search\\_result&selectedTitle=2~143&usage type=default&display rank=1#H14130832](https://www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects?search=direct%20oral%20anticoagulants&source=search_result&selectedTitle=2~143&usage%20type=default&display%20rank=1#H14130832) on the 13<sup>th</sup> January 2021